An Adjuvant Endocrine-based Therapy Study of Camizestrant (AZD9833) in ER+/HER2- Early Breast Cancer (CAMBRIA-2)
Status:
Recruiting
Trial end date:
2037-05-06
Target enrollment:
Participant gender:
Summary
This is a Phase III open-label study to assess if camizestrant improves outcomes compared to
standard adjuvant endocrine therapy for patients with ER+/HER2- early breast cancer with
intermediate-high or high risk for disease recurrence who completed definitive locoregional
therapy (with or without chemotherapy). The planned duration of treatment in either arm
within the study will be 7 years.
Phase:
Phase 3
Details
Lead Sponsor:
AstraZeneca
Collaborator:
Austrian Breast and Colorectal Cancer Study Group (ABCSG)